CoChat

Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications

Open access
Berlanga‐Acosta, Jorge, Gavilondo‐Cowley, Jorge, López‐Saura, Pedro, González‐López, Tania, Castro‐Santana, María D, López‐Mola, Ernesto, Guillén‐Nieto, Gerardo, Herrera‐Martinez, Luis · 2009 · International Wound Journal
Cited by 168

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Chemotaxis, mitogenesis, motogenesis and cytoprotection are common cellular events involved in both tumourigenesis and tissue repair, which appear amplified upon growth factors exposure. Epidermal growth factor (EGF) promotes these events in epithelial and mesenchymal cells through the binding to a specific tyrosine kinase receptor. In experimental oncology settings, EGF does not initiate malignant transformation but exhibits ‘tumour promotion’. These observations have raised doubts on the clinical use of EGF despite solid demonstrations of efficacy in experimental conditions and clinical trials. The results of a Pubmed and Bioline investigation on EGF clinical uses and preclinical safety data are presented here. EGF topical administration has been used since 1989 to enhance the healing process of a variety of peripheral tissues wounds (16 clinical reports), as well as its intravenous, oral and rectal administration for gastrointestinal damages (11 clinical reports). EGF therapeutic efficacy and excellent tolerability seem demonstrated. Lack of long‐term adverse effects is highlighted in those studies with 6, 12 and 24 months of patients follow‐up. Although post‐treatment follow‐up may fall short for malignant growth, there are no reports on evidences linking EGF clinical use with cancer. A multicentre, nationwide survey in Cuba, 15 years after randomly using silver sulphadiazine with EGF or not in burn victims yielded that cancer incidence was comparable between EGF‐treated and control subjects and that such incidence rate does not differ from the age‐matched national incidence for those 15‐year period. All the animal species subjected to long‐term EGF systemic administration exhibit dose‐dependent and reversible epithelial organs hyperplasia with no changes in cells phenotypic differentiation. Histotypic pre‐malignant markers were not identified. The results emerged from co‐carcinogenesis studies and from transgenic mice over‐expressing EGF are conflicting and indicate that EGF overexposure, either innate or postnatal, may not be sufficient to transform cells. The ability of EGF to heal injured tissues in life‐threatening scenarios or to assist in preventing physical and social disability advocates for its clinical use under a rational medical risk/benefit balance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-481x.2009.00622.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 168

Metadata

Authors
Berlanga‐Acosta, J., Gavilondo‐Cowley, J., López‐Saura, P., González‐López, T., Castro‐Santana, M. D., López‐Mola, E., Guillén‐Nieto, G., & Herrera‐Martinez, L.
Venue
International Wound Journal
Publisher
Wiley
Published
2009-10
Volume
6
Issue
5
Pages
331-346
ISSN
  • 1742-4801 (ISSN-L)
  • 1742-481X
OpenAlex
W2028839182
Cited by
168
References
8
FWCI
3.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications. https://app.cochat.ai/papers/10.1111/j.1742-481x.2009.00622.x
The paper
Berlanga‐Acosta, J., Gavilondo‐Cowley, J., López‐Saura, P., González‐López, T., Castro‐Santana, M. D., López‐Mola, E., Guillén‐Nieto, G., & Herrera‐Martinez, L. (2009). Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications. International Wound Journal. https://doi.org/10.1111/j.1742-481x.2009.00622.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.